Better Buy: Pfizer Inc. vs. Johnson & Johnson
With only one month remaining in 2017, it's pretty clear which big pharma stock has been the better pick this year between Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ). J&J's share price is up more than 20%, while Pfizer stock is only up a little over half as much.
Investing is kind of like driving, though. It's much more important to look ahead than it is to focus on what's in the rearview mirror. Which of these stocks is the better choice for investors in the years to come? Here's how Pfizer and Johnson & Johnson compare in three key categories.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€26.77
2.820%
With 29 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 40 € there is a positive potential of 49.42% for Pfizer Inc. compared to the current price of 26.77 €.
